N
← Back to Search
Sponsored

Accelerate Your Clinical Trial Recruitment

Reach thousands of high-intent patients matching your specific inclusion criteria.

Start Campaign
RECRUITING Phase 1 ClinicalTrials.gov

Inhaled Ciclesonide Study in Preterm Infants

Sponsor: Venkatesh Sampath • ClinicalTrials.gov ID: NCT06589245

Registry updated: 2026-09-09
Ad

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Check Eligibility →

Description

Our overall objective is to conduct a safety study with inhaled ciclesonide to evaluate known glucocorticoids (sGC)-related acute and intermediate toxic effects while measuring for the first time in neonates its systemic absorption and potential bioactivity (i.e. activation of primary target, the GR, in blood cells).

Interventions

  • Alvesco Inhalant Product (Drug)
    Inhaled Alvesco will be administered daily for 14 days at escalating doses of 80mcg and 160mcg.

Eligibility criteria

Inclusion Criteria: * Viable Infants born between 23 0/7 - 29 6/7 gestation * Requiring invasive (through an endotracheal tube) mechanical ventilation * Between day of life 8 to 35. * Infants have not received dexamethasone for 120 hours * If receiving hydrocortisone, then receiving ≤ 1mg/kg/day Exclusion Criteria: * Infants with major congenital lung or other organ anomalies, life-threatening illness, active sepsis or NEC, and grade IV hemorrhage will be excluded. * Infants receiving DEX therapy will be excluded. * We will exclude infants who have had ≥ 1 glucose level \> 150mg in the 24 hours prior to study entry or those on insulin therapy to treat hyperglycemia. We will exclude infants who have hypertension (\>95% centile for gestational age) in the 48 hours prior to study entry. * For small for gestational age, we will exclude infants with a birthweight \< 5% centile for gestational age. * Infants with history of recent pulmonary hemorrhage (within 72 hours of study entry) will also be excluded. * Infants receiving or have received any dexamethasone in the prior 120 hours. * Infants receiving \>1mg/kg/day of hydrocortisone. * Infants receiving any other inhaled or systemic steroid.

Conditions

Bronchopulmonary Dysplasia

Locations

  • Children's Mercy Kansas City — Kansas City, Missouri, United States
Sponsored

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record